Journal
EMERGING INFECTIOUS DISEASES
Volume 14, Issue 11, Pages 1689-1692Publisher
CENTERS DISEASE CONTROL
DOI: 10.3201/eid1411.080431
Keywords
-
Categories
Funding
- NIH National Institute of Allergy and Infectious Diseases [U54 AI065357]
- Wellcome Trust
Ask authors/readers for more resources
Genetic research into the select agents Burkholderia pseudomallei and B. mallei is currently hampered by a paucity of approved antimicrobial drug-selection markers. The strict regulations imposed on researchers in the United States but not in other parts of the world lead to discrepancies in practice, hinder distribution of genetically modified strains, and impede progress in the field. Deliberation and decisions regarding alternative selection markers (antimicrobial and nonantimicrobial drugs) by the international community, regulatory authorities, and funding agencies are needed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available